Check Your Eligibility
All calculations are done locally in your browser. Nothing is stored or transmitted.
FDA Eligibility Criteria — All GLP-1 Drugs
| Drug | FDA Indication | BMI Requirement | Additional Requirements |
|---|---|---|---|
| Ozempic (semaglutide) | Type 2 diabetes, CV risk | None (T2D required) | Diagnosed type 2 diabetes |
| Wegovy (semaglutide 2.4mg) | Weight management, CV risk | BMI ≥30, or ≥27 with comorbidity | Adults (18+); comorbidity if BMI 27–29 |
| Mounjaro (tirzepatide) | Type 2 diabetes | None (T2D required) | Diagnosed type 2 diabetes |
| Zepbound (tirzepatide) | Weight management, sleep apnea | BMI ≥30, or ≥27 with comorbidity | Adults (18+); comorbidity if BMI 27–29 |
| Saxenda (liraglutide) | Weight management | BMI ≥30, or ≥27 with comorbidity | Adults (18+) and adolescents 12+ |
| Wegovy (adolescent) | Weight management | BMI ≥95th percentile for age/sex | Ages 12–17 |
💡 Even if you meet eligibility criteria, you still need a prescription from a licensed healthcare provider. A doctor may also prescribe GLP-1 medications off-label for conditions not listed above — eligibility criteria are guidelines, not hard rules.
Qualifying Comorbidities for BMI 27–29
If your BMI is between 27 and 29.9 (overweight but not obese), you qualify for Wegovy and Zepbound if you have at least one of the following weight-related conditions:
- Hypertension — high blood pressure (diagnosed or on medication)
- Type 2 diabetes — diagnosed or pre-diabetes in some cases
- Dyslipidemia — high cholesterol, high LDL, high triglycerides, or low HDL
- Obstructive sleep apnea — diagnosed, with or without CPAP treatment
- Cardiovascular disease — for Wegovy specifically (SELECT trial approval)
⚠️ Insurance coverage often uses stricter criteria than FDA approval. Even if you meet FDA eligibility, your specific insurance plan may require a higher BMI, documented treatment failures, or additional comorbidities for prior authorization approval.